Mark Goldberger
Impact in
-
- Antibiotic Use and Resistance
- Molecular Medicine top 5%
- Antibiotic Resistance in Bacteria
Papers in
-
- Antibiotics Pharmacokinetics and Efficacy 7
- Pharmacogenetics and Drug Metabolism 2
- Drug-Induced Adverse Reactions 2
-
- Antibiotic Resistance in Bacteria 6
- Co-authors
- Jerrold J. Ellner (2 shared papers)David M. Parenti (1 shared paper)John Rex (4 shared papers)Barry I. Eisenstein (4 shared papers)John Tomayko (3 shared papers)Aaron Dane (2 shared papers)M D Iseman (1 shared paper)A. R. Hinman (1 shared paper)
- Journals
- The Journal of Infectious Diseases (2 papers)Clinical Infectious Diseases (2 papers)Clinical Pharmacology & Therapeutics (2 papers)American Journal of Health-System Pharmacy (1 paper)Infection (1 paper)
- Partner nations
- United StatesUnited KingdomCanada
In The Last Decade
Mark Goldberger
17 papers receiving 550 citations
Peers
Comparison fields: 5 of 92
- Applied Microbiology and Biotechnology 73
- Molecular Medicine 114
- Infectious Diseases 255
- Epidemiology 246
- Pharmacology 80
Countries citing papers authored by Mark Goldberger
This map shows the geographic impact of Mark Goldberger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Goldberger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Goldberger more than expected).
Fields of papers citing papers by Mark Goldberger
This network shows the impact of papers produced by Mark Goldberger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Goldberger. The network helps show where Mark Goldberger may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark Goldberger, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 1991 | 191 | |
| 2 | 1993 | 93 | |
| 3 | 2013 | 92 | |
| 4 | 2017 | 47 | |
| 5 | 1983 | 26 | |
| 6 | 2002 | 25 | |
| 7 | 2014 | 23 | |
| 8 | 2002 | 18 | |
| 9 | 2021 | 17 | |
| 10 | 1976 | 14 | |
| 11 | 2014 | 13 | |
| 12 | 1988 | 11 | |
| 13 | 2010 | 7 | |
| 14 | 1978 | 5 | |
| 15 | 1978 | 2 | |
| 16 | 1997 | 2 | |
| 17 | 2016 | 1 |
About Mark Goldberger
Mark Goldberger is a scholar working on Pharmacology, Molecular Medicine, Infectious Diseases, Surgery and Economics and Econometrics, having authored 17 papers that have together received 587 indexed citations. Recurring topics across this work include Antibiotics Pharmacokinetics and Efficacy (7 papers), Antibiotic Resistance in Bacteria (6 papers), Antibiotic Use and Resistance (3 papers), Tuberculosis Research and Epidemiology (3 papers), Health Systems, Economic Evaluations, Quality of Life (3 papers), Pharmacogenetics and Drug Metabolism (2 papers), Mycobacterium research and diagnosis (2 papers) and Drug-Induced Adverse Reactions (2 papers). The work is most often cited by research in Applied Microbiology and Biotechnology (73 citations), Molecular Medicine (114 citations), Infectious Diseases (255 citations), Epidemiology (246 citations) and Pharmacology (80 citations). Mark Goldberger has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Jerrold J. Ellner, David M. Parenti, John Rex, Barry I. Eisenstein, John Tomayko, Aaron Dane, M D Iseman, A. R. Hinman, Kent A. Sepkowitz and Margaret A. Fischl. Their work appears in journals such as The Journal of Infectious Diseases, Clinical Infectious Diseases, Clinical Pharmacology & Therapeutics, American Journal of Health-System Pharmacy and Infection.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.